This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Sanofi and Regeneron Pharmaceuticals, Inc.
Reference
Muszbek N, et al. Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs. Advances in Therapy : 19 Apr 2019. Available from: URL: http://doi.org/10.1007/s12325-019-00946-1
Rights and permissions
About this article
Cite this article
Sarilumab cost effective in RA not responding to traditional DMARDs. PharmacoEcon Outcomes News 827, 31 (2019). https://doi.org/10.1007/s40274-019-5869-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5869-7